- Home
- AAUC vs DNLI Comparison
AAUC vs DNLI Comparison
Compare AAUC & DNLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AAUC | DNLI |
|---|---|---|
| Founded | N/A | 2013 |
| Country | Canada | United States |
| Employees | 2252 | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.9B | 3.2B |
| IPO Year | N/A | 2017 |
Fundamental Metrics
Financial Performance| Metric | AAUC | DNLI |
|---|---|---|
| Price | $31.27 | $19.73 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 11 |
| Target Price | N/A | ★ $30.00 |
| AVG Volume (30 Days) | 315.3K | ★ 1.4M |
| Earning Date | 01-01-0001 | 05-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $81.96 | N/A |
| Revenue Next Year | $57.34 | $291.12 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $11.40 | $10.57 |
| 52 Week High | $32.08 | $23.77 |
Technical Indicators
Market Signals| Indicator | AAUC | DNLI |
|---|---|---|
| Relative Strength Index (RSI) | 60.78 | 45.90 |
| Support Level | $31.00 | $13.28 |
| Resistance Level | $32.08 | $20.12 |
| Average True Range (ATR) | 0.29 | 1.11 |
| MACD | -0.23 | -0.15 |
| Stochastic Oscillator | 40.85 | 25.00 |
Price Performance
Historical ComparisonAbout AAUC Allied Gold Corporation
Allied Gold Corp is a company focused on gold mining activities in Africa. Allied has three mines and several development and exploration projects in Africa where it has operating experience. Operations are located in Cote d'Ivoire, Mali, and Ethiopia. The company expands and optimizes initiatives at existing operating mines, the development of new mines, the advancement of its exploration properties, and, targeting other consolidation opportunities with a focus on Africa.
About DNLI Denali Therapeutics Inc.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.